Sarah Gheuens Sells 30,000 Shares of Agios Pharmaceuticals (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total transaction of $914,400.00. Following the transaction, the insider directly owned 54,645 shares of the company’s stock, valued at $1,665,579.60. This represents a 35.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Agios Pharmaceuticals Trading Up 1.0%

NASDAQ AGIO opened at $32.27 on Friday. The firm has a market cap of $1.93 billion, a price-to-earnings ratio of -4.60 and a beta of 0.58. The company has a 50 day moving average of $34.75 and a 200-day moving average of $31.01. Agios Pharmaceuticals, Inc. has a 1-year low of $22.24 and a 1-year high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%.The business had revenue of $44.75 million during the quarter, compared to analyst estimates of $26.39 million. On average, analysts forecast that Agios Pharmaceuticals, Inc. will post -6.12 earnings per share for the current year.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several institutional investors have recently modified their holdings of AGIO. BlackRock Inc. bought a new stake in Agios Pharmaceuticals in the second quarter valued at approximately $239,582,000. Wellington Management Group LLP grew its holdings in shares of Agios Pharmaceuticals by 485.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after buying an additional 2,049,287 shares during the period. MPM Bioimpact LLC bought a new stake in shares of Agios Pharmaceuticals in the 4th quarter valued at $35,478,000. State Street Corp raised its stake in Agios Pharmaceuticals by 37.4% during the 4th quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock worth $84,604,000 after buying an additional 845,433 shares during the period. Finally, TCG Crossover Management LLC lifted its holdings in Agios Pharmaceuticals by 105.2% during the third quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock worth $57,402,000 after acquiring an additional 733,038 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on AGIO shares. Citigroup lifted their price target on Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a report on Friday, July 31st. HC Wainwright increased their price objective on Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. JPMorgan Chase & Co. lifted their target price on Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a “neutral” rating in a research note on Friday. Royal Bank Of Canada boosted their target price on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research report on Tuesday, July 7th. Finally, Bank of America raised their price target on Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. Five analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $41.25.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.